The national expert group on vaccine administration for COVID-19 met representatives of leading domestic manufactures, including Serum Institute of India, Bharat Biotech and Zydus Cadila, on August 17 to take inputs about the present stage of various candidate vaccines as well as their expectations from the government, the Union Health Ministry said.
For our comprehensive coverage and latest updates on COVID-19 click here.
The meeting was mutually beneficial and productive, the ministry said. "It provided the national expert group with inputs about the present stage of various candidate vaccines being developed by indigenous manufacturers as well as their expectations from the Union government," the statement said.
The meeting was chaired by the Niti Aayog member and co-chaired by the Union Health Secretary. The panel met separately representatives of the five firms -- Serum Institute of India (Pune), Bharat Biotech (Hyderabad), Zydus Cadila (Ahmedabad), Gennova Biopharmaceuticals (Pune) and Biological E (Hyderabad). According to sources, the panel comprising the Department of Biotechnology Secretary, the ICMR Director General and the Department of Pharmaceuticals Secretary met the representatives of the five pharma firms and asked them about their production capacity and whether they need any sort of assistance from the government.
This was the second meeting of the committee after August 12. In the first meeting, it delved into the procurement mechanism for COVID-19 vaccine, including both indigenous and international manufacturing along with guiding principles for prioritisation of population groups for vaccination. The expert group had then held discussions on financial resources required for procurement of COVID-19 vaccine and various options of financing the same. Available options in terms of delivery platforms, cold chain and associated infrastructure for roll out of COVID-19 vaccination were also taken up. Further, strategy and follow-up action on all possible scenarios to ensure equitable and transparent delivery of vaccine was deliberated upon.
The phase-1 human clinical trials of the two COVID-19 vaccine candidates developed indigenously by Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd have been completed and the trials have moved to phase 2, the ICMR Director General had said at a press briefing recently.
The Serum Institute of India, which has partnered with AstraZeneca for manufacturing the COVID-19 vaccine candidate developed by the University of Oxford, has been permitted for conducting Phases 2 and 3 human clinical trials of the candidate in India. It is likely to start the trials soon.
Biological E Ltd has entered into an agreement with Janssen Pharmaceutica NV, part of pharma major Johnson & Johnson, for creation and enhancement of production capabilities to manufacture the latter's COVID-19 vaccine. In collaboration with HDT Biotech Corporation, USA, Gennova has developed an mRNA vaccine candidate (HGCO19), with demonstrated safety, immunogenicity, neutralisation antibody activity in rodent and non-human primate models. It is likely to go to clinical trial before the year-end.
